Helicobacter pylori is a Gram-negative bacterium responsible for the development of gastric diseases. The issue of spreading antibiotic resistance of H. pylori and its limited therapeutic options is an important topic in modern gastroenterology. This phenomenon is greatly associated with a very narrow range of antibiotics used in standard therapies and, as a consequence, an alarmingly high detection of multidrug-resistant H. pylori strains. For this reason, scientists are increasingly focused on the search for new substances that will not only exhibit antibacterial effect against H. pylori, but also potentiate the activity of antibiotics. The aim of the current review is to present scientific reports showing newly discovered or repurposed compounds with an ability to enhance the antimicrobial activity of classically used antibiotics against H. pylori. To gain a broader context in their future application in therapies of H. pylori infections, their antimicrobial properties, such as minimal inhibitory concentrations and minimal bactericidal concentrations, dose- and time-dependent mode of action, and, if characterized, anti-biofilm and/or in vivo activity are further described. The authors of this review hope that this article will encourage the scientific community to expand research on the important issue of synergistic therapies in the context of combating H. pylori infections.

中文翻译：

---

协同疗法作为抗药性幽门螺杆菌的有前途的选择

幽门螺杆菌是引起胃部疾病发展的革兰氏阴性细菌。幽门螺杆菌的抗生素耐药性扩散问题及其有限的治疗选择是现代胃肠病学中的重要课题。这种现象与标准疗法中使用的抗生素范围非常窄有关，因此，对耐多药幽门螺杆菌菌株的检测令人震惊地高。因此，科学家越来越专注于寻找不仅对幽门螺杆菌具有抗菌作用的新物质。，还可以增强抗生素的活性。本综述的目的是提出科学报告，显示新发现或重新使用的具有增强传统使用的抗生素对幽门螺杆菌抗菌活性的化合物。为了在其将来用于幽门螺杆菌感染的治疗中获得更广阔的背景，它们的抗菌特性，例如最小的抑制浓度和最小的杀菌浓度，剂量和时间依赖性的作用方式，以及（如果有特征的话）抗生物膜和/或体内活性进一步描述。这篇评论的作者希望本文能够鼓励科学界在对抗疾病的背景下扩大对协同疗法这一重要问题的研究。幽门螺杆菌感染。